Clinical Trials Logo

Clinical Trial Summary

The purpose of the trial is to evaluate the PK, bioavailability, PD, efficacy and safety of MarzAA for on demand treatment and control of bleeding episodes in adult subjects with inherited bleeding disorders.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04548791
Study type Interventional
Source Catalyst Biosciences
Status Terminated
Phase Phase 1/Phase 2
Start date May 17, 2021
Completion date December 3, 2021

See also
  Status Clinical Trial Phase
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Not yet recruiting NCT02554526 - Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Active, not recruiting NCT03619863 - ATHN 7: Hemophilia Natural History Study
Completed NCT03951103 - rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
Terminated NCT04303572 - The Hemophilia Inhibitor Eradication Trial Phase 3
Terminated NCT04489537 - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B Phase 3
Recruiting NCT04647227 - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors Phase 4
Completed NCT03372993 - Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Terminated NCT03204539 - INdividualized ITI Based on Fviii(ATE) Protection by VWF Phase 4
Active, not recruiting NCT04205175 - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab Phase 4
Recruiting NCT03598725 - Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China Phase 4
Completed NCT04723693 - An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Completed NCT04789954 - Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors Early Phase 1
Recruiting NCT04592692 - A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip Phase 2
Completed NCT03407651 - Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B Phase 2
Active, not recruiting NCT05651061 - A Phase I of SS109 in Hemophilia A or and B With Inhibitors Phase 1
Recruiting NCT04684940 - Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors Phase 1/Phase 2
Recruiting NCT04768699 - Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. Phase 1
Recruiting NCT04805801 - The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors